AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

The expectation is for Q2 earnings to increase by +5% from the same period last year on +4% higher revenues. This will be a material deceleration from the growth trend of recent quarters and will ...

AbbVie (ABBV) closed at $182.31 in the latest trading session, marking a -2.4% move from the prior day.

US Stocks Likely To Open Higher Despite Powell's Tariff-Induced Inflation Warning: Walgreens, Nike In Focus Ahead Of Earnings ...

Making Sense of Earnings Expectations for 2025 Q2 and Beyond The start of Q2 coincided with heightened tariff uncertainty following the punitive April 2 nd tariff announcements.

Image source: The Motley Fool. DATE Tuesday, June 24, 2025 at 9 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Patrick ZammitChief Financial Officer — Marshall Witt Need a quote from one ...

AbbVie is expected to post earnings of $3.24 per share for the current quarter, representing a year-over-year change of +22.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

KB Home (NYSE:KBH) stock slid 2.9% in Monday after-hours trading after the homebuilder trimmed its full-year guidance even as the company's fiscal Q2 earnings and revenue exceeded the average ...